Every 424B that Coherus Oncology, Inc. (CHRS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CHRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CHRS filings page.
Coherus Oncology, Inc. (CHRS) filed a prospectus supplement establishing an at-the-market equity program to issue and sell up to $50,000,000 of common stock under its existing $150.0 million shelf registration. Sales will be made from time to time through Leerink Partners LLC as sales agent on the Nasdaq Global Market.
Leerink Partners may conduct sales deemed to be an “at the market offering” under Rule 415, earning up to 3.0% of gross proceeds plus up to $100,000 of reimbursed legal expenses. Coherus expects to use any net proceeds for general corporate purposes, including working capital, R&D, commercial activities and capital expenditures, pending investment in short-term investment-grade securities.
The company highlights risks including potential dilution to investors, fluctuating share sale prices under the ATM, and significant indebtedness under a Loan and Security Agreement with Innovatus Life Sciences Lending Fund I, LP, which imposes financial and operational covenants and could adversely affect liquidity if breached.
Coherus Oncology, Inc. (CHRS) is formally ending its existing at-the-market equity offering program under a prior sales agreement. Under that agreement, the company could offer and sell common stock with an aggregate offering price of up to $92,500,000, and had previously registered the offer and sale of up to $64,880,054 of common stock under a January 2026 prospectus. On August 17, 2026, Coherus notified the agent that it was terminating the sales agreement because it is entering into a new sales agreement with a different agent. This supplement terminates the continuous offering under the January 2026 prospectus and the related sales agreement.
Coherus Oncology, Inc. is conducting a primary offering of 28,600,000 shares of common stock at $1.75 per share, with expected net proceeds of about $46.5 million, plus a 30‑day option for underwriters to buy up to 4,290,000 additional shares.
The company plans to use the funds to support commercialization of LOQTORZI, advance clinical development of its oncology pipeline, and for working capital and general corporate purposes. Preliminary 2025 results show estimated net revenue of $42.2 million, up from $26.4 million in 2024, driven largely by $40.8 million of LOQTORZI sales.
Cash, cash equivalents and marketable securities are estimated at $172.1 million as of December 31, 2025, and Coherus expects this liquidity to fund operations through the end of 2026, while still recording a loss from continuing operations for the fourth quarter of 2025.
Coherus Oncology is launching a public offering of common stock from its existing shelf registration. The company plans to use proceeds to support commercialization of LOQTORZI, advance clinical development of its oncology pipeline, and for working capital and general corporate purposes.
Preliminary unaudited results for 2025 show net revenue from continuing operations of about $12.7 million for Q4 (vs. $7.7 million a year earlier) and $42.2 million for the full year (vs. $26.4 million), with LOQTORZI contributing most of these amounts. Cash, cash equivalents and marketable securities were approximately $172.1 million as of December 31, 2025, which the company expects will fund operations through the end of 2026.
Coherus describes positive clinical data for LOQTORZI in nasopharyngeal cancer, including a Phase 3 trial showing median overall survival of 64.8 months with LOQTORZI plus chemotherapy versus 33.7 months with chemotherapy alone and an observed 38% reduction in risk of death. Additional Phase 2 data for casdozokitug in liver cancer showed an overall response rate of 38% and complete response rate of 17% in combination therapy, with no new safety signals reported.
Coherus Oncology, Inc. is registering and offering up to $64,880,054 of its common stock through an at‑the‑market sales program with TD Cowen under an existing Form S-3 shelf. TD Cowen may sell shares into the Nasdaq Global Market under the symbol CHRS and will receive up to 3.0% of gross proceeds as commissions.
The company intends to use any net proceeds for general corporate purposes, including working capital, research and development, commercial activities and capital spending. Coherus reports preliminary unaudited net revenue from continuing operations of approximately $12.7 million for the quarter and $42.2 million for the year ended December 31, 2025, up from $7.7 million and $26.4 million a year earlier, and estimates cash, cash equivalents and marketable securities of about $172.1 million as of December 31, 2025.